Kerecis, a manufacturer of tissue-regeneration materials, has completed the first human clinical trial of its MariGen Lipid Collagen Matrix.
The MariGen Lipid Collagen Matrix is a marine-derived tissue regeneration product containing intact collagen and fish-skin derived Omega 3 oils used to treat chronic wounds and for abdominal wall reconstruction.
The trial enrolled ten patients with serious non-healing wounds who received treatment with the MariGen matrix for 28 days.
Kerecis managing director Baldur Tumi Baldursson said that the results of the study demonstrate the safety of the MariGen Lipid Collagen Matrix technology and indicate the efficacy of the product.
"By the end of the study all ten wounds had improved, with six completely healing," Baldursson added.
Kerecis Clinical R&D director Hilmar Kjartansson said that the company’s next step is a multicentre efficacy study with more patients.
"We are currently working on establishing partnerships with clinicians in the US, Europe and Australia to partner with us in such a trial," Kjartansson added.